v3.26.1
Revenues
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenues
Note 3. Revenues
Revenues are recognized under guidance within ASC 606, Revenue from Contracts with Customers. The following table presents our disaggregated revenue for the periods presented (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
JAKAFI net sales1
$816,659 $763,788 $1,574,414 $1,473,200 
OPZELURA net sales2
449,736 164,499 592,751 283,204 
ICLUSIG net sales34,394 32,729 69,857 62,273 
PEMAZYRE net sales23,418 22,192 45,961 40,632 
MINJUVI/MONJUVI net sales53,686 31,131 102,913 60,682 
NIKTIMVO net sales60,309 36,154 115,397 49,767 
ZYNYZ net sales49,947 8,921 91,340 11,930 
Total net sales1,488,149 1,059,414 2,592,633 1,981,688 
JAKAVI product royalty revenues124,190 109,714 229,746 201,859 
OLUMIANT product royalty revenues38,479 33,482 74,886 64,282 
TABRECTA product royalty revenues6,691 6,632 12,673 13,045 
Other product royalty revenues5,330 1,287 8,577 2,553 
Total product royalty revenues174,690 151,115 325,882 281,739 
Milestone and contract revenues11,200 5,000 28,200 5,000 
Total revenues$1,674,039 $1,215,529 $2,946,715 $2,268,427 
1 Second quarter 2026 JAKAFI net sales include JAKAFI and JAKAFI XR following the launch of JAKAFI XR in the second quarter of 2026.
2 Second quarter 2026 OPZELURA net sales includes $246.0 million related to our agreement with CMS to resolve our litigation related to the application of Medicaid rebate rules to OPZELURA. Refer to Note 15 for further information.
For further information on our revenue-generating contracts, refer to Note 7.